1. Pink Sheet

PhRMA And Trump: 'Go Boldly,' Or Tread Carefully?

 
• By Michael McCaughan

Brand name industry’s image campaign promises to 'Go Boldly' – but there has been nothing bold about its public response to the Trump Administration’s efforts to repeal the Affordable Care Act, the President’s strong words on drug pricing, or even proposed cuts to NIH funding and FDA. Treading carefully makes a lot of sense – but is there a line that PhRMA won’t let the Administration cross?

As the House of Representatives began the process of marking up the American Health Care Act – better known as the Obamacare “Repeal and Replace” Bill – here is what some key constituencies had to say:

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access